Clinical Trial Update: RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe [Phase 2]

View source ↗

Summary

Phase 2 trial RAPTOR evaluated RAD001 (everolimus) as monotherapy for advanced papillary renal cell carcinoma; the study is completed with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2015-11-26